Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities

Poor pharmacokinetics and resistance within some tumor cell lines have been the major obstacles during the preclinical or clinical application of TRAIL (tumor-necrosis-factor (TNF)-related apoptosis-inducing ligand). The half-life of TRAIL(114-281) (114 to 281 amino acids) was revealed to be no more...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Pan, Li-Qiang, Zhao, Wen-Bin, Lai, Jun, Ding, Ding, Wei, Xiao-Yue, Li, Yang-Yang, Liu, Wen-Hui, Yang, Xiao-Yue, Xu, Ying-Chun, Chen, Shu-Qing
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4597189/
https://ncbi.nlm.nih.gov/pubmed/26445897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep14872
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados